Molecular Partners plans cuts of up to 44% as focus shifts
Key points
- Molecular Partners (NASDAQ:MOLN) plans to cut up to approximately 44% of its workforce, affecting no more than 55 positions, as it sharpens its focus on targeted radiotherapy.
- Dosing continues in the fully recruited second dose level of the MP0712 Phase 1/2a study, with initial safety data expected in December 2026.
- The company reported CHF 57.5 million in cash and cash equivalents at September 30, 2026, and expects funding to last into late 2027 under current operating assumptions.
Molecular Partners (NASDAQ:MOLN) plans to reduce its workforce by up to approximately 44%, affecting no more than 55 positions, as it increases its focus on targeted radiotherapy.
The company has started employee consultations, with implementation expected by the second quarter of 2027 and the full cost reductions expected to take effect in early second-half 2027.
Dosing continues in the fully recruited second dose level of the MP0712 Phase 1/2a study, with no dose-limiting events reported in the first dose level and adverse events described as mild to moderate and transient
The company expects initial MP0712 safety data in December 2026 and efficacy data in 2027, while other radiotherapy programmes continue to advance.
Molecular Partners held CHF 57.5 million in cash and cash equivalents at September 30, 2026, expects funding to last into late 2027 under current operating assumptions, and forecasts 2026 operating expenses of CHF 50 million–CHF 55 million at constant exchange rates.
Frequently asked questions
More from United States
STMicroelectronics records 17.9% Q3 revenue increase to $3.76B
AB InBev Q3 revenue jumps 9.1% to $16.51 billion
Takeda upgrades FY2026 outlook after 8.4% revenue growth
ASE Technology posts 44.8% Q3 revenue growth to NT$244.2 billion
Magnum Ice Cream Q3 revenue rises 12.1% to €2.51 billion
Shell Q3 adjusted earnings rise to $10.8 billion
